Therapeutic effect of N-Acetyl-Seryl-Aspartyl-Proline and Vasoactive Intestinal Peptide on COPD pathophysiology.

COPD as an inflammatory respiratory system disease is caused by exposure to cigarette smoke and tobacco in long-term. Some anti-inflammatory peptides can control inflammation in COPD. Ac-SDKP and VIP as peptide have anti-inflammatory effect and, in this study, the effect of Ac-SDKP and VIP on COPD inflammation was studied. After producing cigarette smoke induced COPD mice model, which were treated with VIP and Ac-SDKP. The levels Antioxidant related factors, (MDA and SOD), Fibrotic factors (HP and TGF-β), pro-inflammatory cytokines (TNF-α, IL-1β and IL-6), and inflammation in histopathological examination were studied. MDA, Remodeling factors, pro-inflammatory cytokines, and inflammation in lung tissue were controlled by VIP and Ac-SDKP treatment. These treatments could enhance SOD. VIP and Ac-SDKP as immuno- regulatory factors had benefit effect in treatment of COPD. The anti-inflammatory, anti-fibrosis and anti-oxidant property of VIP and Ac-SDKP may be effective therapy in COPD. This article is protected by copyright. All rights reserved.